These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 25747275)
1. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. Khalil HS; Mitev V; Vlaykova T; Cavicchi L; Zhelev N J Biotechnol; 2015 May; 202():40-9. PubMed ID: 25747275 [TBL] [Abstract][Full Text] [Related]
3. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Fischer PM; Gianella-Borradori A Expert Opin Investig Drugs; 2005 Apr; 14(4):457-77. PubMed ID: 15882121 [TBL] [Abstract][Full Text] [Related]
4. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines. Coley HM; Shotton CF; Kokkinos MI; Thomas H Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833 [TBL] [Abstract][Full Text] [Related]
6. The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. Whittaker SR; Te Poele RH; Chan F; Linardopoulos S; Walton MI; Garrett MD; Workman P Cell Cycle; 2007 Dec; 6(24):3114-31. PubMed ID: 18075315 [TBL] [Abstract][Full Text] [Related]
7. Treatment with a cyclin-dependent kinase inhibitor, seliciclib, is effective in reducing glomerular macrophage numbers and the severity of established experimental glomerulonephritis. Sheryanna AM; Smith J; Bhangal G; Barnett A; McClue S; Tam FW; Cook T; Pusey CD Nephrology (Carlton); 2011 May; 16(4):410-6. PubMed ID: 21518118 [TBL] [Abstract][Full Text] [Related]
8. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Lacrima K; Rinaldi A; Vignati S; Martin V; Tibiletti MG; Gaidano G; Catapano CV; Bertoni F Leuk Lymphoma; 2007 Jan; 48(1):158-67. PubMed ID: 17325859 [TBL] [Abstract][Full Text] [Related]
10. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770 [TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases. Liebl J; Krystof V; Vereb G; Takács L; Strnad M; Pechan P; Havlicek L; Zatloukal M; Fürst R; Vollmar AM; Zahler S Angiogenesis; 2011 Sep; 14(3):281-91. PubMed ID: 21487803 [TBL] [Abstract][Full Text] [Related]
12. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403 [TBL] [Abstract][Full Text] [Related]
13. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Appleyard MV; O'Neill MA; Murray KE; Paulin FE; Bray SE; Kernohan NM; Levison DA; Lane DP; Thompson AM Int J Cancer; 2009 Jan; 124(2):465-72. PubMed ID: 19003963 [TBL] [Abstract][Full Text] [Related]
14. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471 [TBL] [Abstract][Full Text] [Related]
15. Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor. Iurisci I; Filipski E; Reinhardt J; Bach S; Gianella-Borradori A; Iacobelli S; Meijer L; Lévi F Cancer Res; 2006 Nov; 66(22):10720-8. PubMed ID: 17108108 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors. Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796 [TBL] [Abstract][Full Text] [Related]
17. Effect of seliciclib (CYC202, R-roscovitine) on lymphocyte alloreactivity and acute kidney allograft rejection in rat. Pezzotta A; Mister M; Monteferrante G; Cassis L; Azzollini N; Aiello S; Satta M; Benigni A; Remuzzi G; Noris M Transplantation; 2008 May; 85(10):1476-82. PubMed ID: 18497689 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases. Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Hui AB; Yue S; Shi W; Alajez NM; Ito E; Green SR; Frame S; O'Sullivan B; Liu FF Clin Cancer Res; 2009 Jun; 15(11):3716-24. PubMed ID: 19470731 [TBL] [Abstract][Full Text] [Related]
20. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine. Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]